Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

January 31, 2012

Conditions
Breast CancerOsteoporosis
Interventions
OTHER

laboratory biomarker analysis

Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.

PROCEDURE

Dual energy X-ray absorptiometry (DEXA)

Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.

PROCEDURE

Spine X-ray

Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.

Trial Locations (16)

34

Instituto Nacional de Enfermedades Neoplasicas, Lima

2031

Institute of Oncology at Prince of Wales Hospital, Randwick

3600

Regionalspital, Thun

4029

Royal Brisbane and Women's Hospital, Brisbane

7925

Groote Schuur Hospital, Cape Town

20141

European Institute of Oncology, Milan

24100

Ospedali Riuniti di Bergamo, Bergamo

28034

Hospital Ruber Internacional, Madrid

33076

Institut Bergonie, Bordeaux

33081

Centro di Riferimento Oncologico - Aviano, Aviano

Unknown

Dunedin Hospital, Dunedin

CH-5001

Kantonspital Aarau, Aarau

CH-3010

Inselspital Bern, Bern

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-6850

Ospedale Beata Vergine, Mendrisio

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

ETOP IBCSG Partners Foundation

NETWORK

NCT00369850 - Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98 | Biotech Hunter | Biotech Hunter